Eficacia de la vacuna recombinante contra el herpes zóster: revisión sistemática

Abstract

Background: Herpes zoster (HZ) is a condition caused by the reactivation of the varicella-zoster virus (VZV). In Europe, the annual incidence of HZ in the general population ranges from 2 to 4.6 cases per 1,000 people yearly, with a notable increase as age advances. This disease is associated with various conditions that affect cellular immunity, such as autoimmune diseases, cancer, immunosuppressive treatments, and certain chronic diseases. Objective: To examine the latest published evidence on the effectiveness of the herpes zoster vaccine, categorized according to its efficacy, efficiency, effectiveness, and safety. Drug interactions will also be addressed. Additionally, current vaccination recommendations will be included. Methodology: A systematic analysis will be conducted using available information from literary databases such as PubMed, Science Direct, SciELO, Elsevier, Cochrane, and Google Scholar, from January 1st, 2020, to August 31st 2024. Updated literature references from Q1 to Q4 quartiles will be included. The review will follow the guidelines of the PRISMA 2020 statement, and the selection of articles will be based on their methodological quality, using the criteria defined in the Oxford scale. Results: The aim is to create a high-quality database on the effectiveness of the herpes zoster vaccine through a review and selection of scientific literature addressing its efficacy, efficiency, effectiveness, and safety. Keywords: adjuvant, efficacy, herpes zoster vaccine, recombinant vaccine, virus